Octreotide dihydrochloride  (Synonyms: SMS 201-995 dihydrochloride)

Octreotide (SMS 201-995) hydrochloride is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly^[1][2].

Octreotide hydrochloride (10^‑8mM, 6 hours) induces phosphorylated‑glycogen synthase kinase 3β (GSK3β) phosphorylation and increases glycogen synthase (GS) activity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Octreotide hydrochloride (subcutaneous injection, 30 mg/kg, once, 8 weeks) can inhibit tumor growth significantly with no effect on body weight^[1].
Octreotide hydrochloride (intramuscular injection, 60 mg/kg, every 21 days, 42 days) inhibits serum insulin-like growth factor (IGF-I) without toxicity in dogs with appendicular osteosarcoma (OSA)^[2].
Octreotide hydrochloride (subcutaneous injection, 40 μg/kg, Every 12 hours, 8 days) improves hepatic glycogen synthesis in obese male Sprague‑Dawley (SD) rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1092.16

C₄₉H₆₈Cl₂N₁₀O₁₀S₂

1607842-55-6

{d-Phe}-cyclo(Cys-Phe-{d-Trp}-Lys-Thr-Cys-{d-Threoninol}) (Disulfide bridge: Cys2-Cys7)

{d-Phe}-cyclo(CF{d-Trp}-KTC)-{d-Threoninol} (Disulfide bridge: Cys2-Cys7)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Octreotide pamoate, OncoLAR, OP-LAR

  [2]. Chand Khanna，et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res. 2002 Jul;8(7):2406-12.  [Content Brief]

  [3]. Xiao-Xia Wang,et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118.  [Content Brief]